The company’s largest shareholder Sofinnova Partners also took part in the round alongside fellow existing backers Morningside Ventures, Alida Capital International and the Scottish Investment Bank.
NuCana said the funds would be used to expand the clinical programme for its lead product, Acelarin, which it said had shown exceptional results in patients with a range of cancers which were resistant to all conventional therapies.
Sofinnova Partners managing partner Rafaèle Tordjman said, “The ProTide technology has already been shown by Gilead to be highly effective for the treatment of HCV and HIV infection, and now NuCana is achieving similar benefits in patients with advanced cancer.
“We are delighted to team up once again with our US colleagues Sofinnova Ventures, and together contribute to building a strong company on the basis of world class science and a talented management team”
Copyright © 2014 AltAssets